Study summary

The purpose of this study is to evaluate the efficacy of enzalutamide with trastuzumab in patients with HER2+ AR+ metastatic or locally advanced breast cancer.

Additional Study Details

Phase
Phase 2
Product
N/A
Product
Enzalutamide
Trastuzumab
Type
Interventional
Masking
None (Open Label)
Enrollment number
103
Show Additional Study Details

Study documents

Protocol
Available Language(s): English, English
Statistical Analysis Plan (SAP)
Available Language(s): English
Plain Language Summary
Available Language(s): English

Get more information

Would you like more information about clinical trial sites that are recruiting participants for A Study to Assess the Efficacy and Safety of Enzalutamide with Trastuzumab in Patients with Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer? Contact us by filling out your information to the right and we’ll respond to you.

  • A caregiver
  • A healthcare provider
  • A parent
  • A patient
  • A patient advocate
  • Algeria
  • Argentina
  • Armenia
  • Australia
  • Austria
  • Belarus
  • Belgium
  • Bosnia And Herzegovina
  • Brazil
  • Bulgaria
  • Canada
  • Chile
  • China
  • Colombia
  • Croatia
  • Czech Republic
  • Denmark
  • Dominican Republic
  • Egypt
  • Estonia
  • Finland
  • Former Serbia and Montenegro
  • France
  • Georgia
  • Germany
  • Greece
  • Guatemala
  • Hong Kong
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Ireland
  • Israel
  • Italy
  • Japan
  • Jordan
  • Kazakhstan
  • Latvia
  • Lebanon
  • Lithuania
  • Macedonia
  • Malaysia
  • Mexico
  • Montenegro
  • Morocco
  • Netherlands
  • New Zealand
  • Norway
  • Panama
  • Peru
  • Philippines
  • Poland
  • Portugal
  • Puerto Rico
  • Republic of Korea
  • Republic of Moldova
  • Romania
  • Russian Federation
  • Saudi Arabia
  • Serbia
  • Singapore
  • Slovakia
  • Slovenia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Taiwan, Province of China
  • Thailand
  • Turkey
  • Ukraine
  • United Kingdom
  • United States
  • Vietnam

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

    Locations

    Contact Us
    Contact Us
    Withdrawn
    Site US10002
    Aurora, CO, United States, 80045
    Completed
    Site GB44013
    Manchester, United Kingdom, M20 4BX
    Withdrawn
    Site US10080
    Whittier, CA, United States, 90603
    Completed
    Site US10042
    Nashville, TN, United States, 37203
    Completed
    Site IT39003
    Milan, Italy, 20132
    Withdrawn
    Site US10031
    Houston, TX, United States, 77030
    Completed
    Site BE32001
    Charleroi, Belgium, 6000
    Completed
    Site IT39002
    Milano, Italy, 20141
    Completed
    Site US10074
    Gainsville, FL, United States, 32605
    Completed
    Site US10077
    Nashville, TN, United States, 37232
    Completed
    Site IT39021
    Udine, Italy, 33100
    Completed
    Site BE32003
    Edegem, Antwerp, Belgium, 2650
    Completed
    Site ES34014
    Pozuelo de Alarcon, Madrid, Spain, 28223
    Withdrawn
    Site US10021
    Chicago, IL, United States, 60611-5975
    Completed
    Site IT39005
    Meldola, Forli, Italy, 47014
    Withdrawn
    Site CA15025
    Montreal, Quebec, Canada, H4A 3J1
    Completed
    Site GB44003
    Edinburgh, United Kingdom, EH4 2XU
    Withdrawn
    Site ES34001
    Lleida, Spain, 25198
    Completed
    Site US10051
    Anaheim, CA, United States, 92801
    Completed
    Site BE32013
    Brasschaat, Belgium, 2930
    Completed
    Site US10076
    Fort Worth, TX, United States, 76104
    Withdrawn
    Site CA15027
    Sault Ste Marie, ON, Canada, P6B 0A8
    Completed
    Site ES34010
    Barcelona, Barcelona, Spain, 08035
    Withdrawn
    Site US10001
    Los Angeles, CA, United States, 90033
    Completed
    Site US10078
    St. Louis, Mo, United States, 63110
    Completed
    Site IT39008
    Lecce, Italy, 73100
    Completed
    Site US10028
    Los Angeles, CA, United States, 90048
    Completed
    Site GB44001
    Nottingham, United Kingdom, NG5 1PB
    Completed
    Site BE32009
    Leuven, Belgium, 3000
    Completed
    Site US10081
    Chicago, IL, United States, 60637
    Completed
    Site US10079
    Fort Myers, FL, United States, 33916
    Completed
    Site BE32016
    Bruxelles, Belgium, 1200
    Completed
    Site US10035
    San Francisco, CA, United States, 94115
    Completed
    Site ES34013
    Madrid, Madrid, Spain, 28050
    Completed
    Site CA15023
    Toronto, ON, Canada, M4N 3M5
    Withdrawn
    Site US10027
    Burbank, CA, United States, 91505
    Completed
    Site US10070
    Boston, MA, United States, 02215
    Completed
    Site BE32007
    Liege, Belgium, 4000
    Completed
    Site US10072
    Cincinnati, OH, United States, 45242
    Withdrawn
    Site BE32017
    Gent, Belgium, 9000
    Completed
    Site CA15026
    Saskatoon, SK, Canada, S7N 4H4
    Active, not recruiting
    Site CA15001
    Quebec, Quebec, Canada, G1S 4L8
    Completed
    Site IT39001
    Sondrio, Italy, 23100
    Completed
    Site CA15028
    Regina, SK, Canada, S4T7T1
    Withdrawn
    Site CA15015
    Edmonton, AB, Canada, T6G 1Z2
    Withdrawn
    Site CA15029
    Montreal, Quebec, Canada, H3G 1L5
    Completed
    Site US10082
    Houston, TX, United States, 77030
    Completed
    Site CA15022
    Ottawa, ON, Canada, K1H 8L6
    Completed
    Site US10029
    Knoxville, TN, United States, 37909
    Completed
    Site US10048
    Pittsburgh, PA, United States, 15213
    Withdrawn
    Site GB44011
    Leeds, United Kingdom, LS7 9TF
    Completed
    Site US10004
    Indianapolis, IN, United States, 46202

    Frequently Asked Questions

    Are clinical trials only for people with advanced cancer?

    While some clinical trials may focus on more advanced cancers, many trials are open to patients at various stages of their cancer. Each study has rules about who can take part. For example, only patients in a certain age group or those who have a certain type of tumor may be able to join.

    Will I have to stop my current treatment to participate in a clinical trial?

    Sometimes researchers want participants to keep taking their current treatments during a clinical trial. Other times, you may need to stop your current treatments for a while. If the investigational treatment doesn't work, you can usually go back to your original treatment plan.

    Should I be worried about getting a placebo?

    In cancer clinical trials, a placebo is only used if there is no other treatment for that type of cancer. This helps compare an investigational treatment to the placebo. Placebos are rarely used in cancer trials because the best available treatment, called the “standard of care”, is usually given instead.

    Do I need a referral from my doctor to take part in a study?

    Your doctor may not know about all the opportunities for clinical trials that are available to you. Talk to your doctor or other medical provider about clinical trial information that you find. They can help you decide if a clinical trial is right for you. If you do not find any options on this website, we recommend you visit an online public registry website like clinicaltrials.gov to see a wide variety of available clinical trials.

    Explore More

    1

    What are clinical trials?

    2

    Why are Clinical Trials Important?

    3

    Why Participate in a Clinical Trial?